According to a new report, pathologists from France and Canada believe
they have been able to identify two test that would help distinguish between
malignant mesothelioma and a benign growth on the mesothelial membrane.
If these tests do work, it could mean for earlier and more accurate detection of
mesothelioma in patients.
Because symptoms of mesothelioma are often similar to other diseases, it
may be difficult to diagnose mesothelioma. However, it’s important
for doctors to diagnose mesothelioma as quickly as possible so they can
provide the necessary treatment to help increase the patient’s chance
of survival. The two molecular tests identified by pathology researchers
can help in providing a fix to this.
The first test uses gene testing to diagnose mesothelioma. It measures
the level of p16 in the patient. This is a tumor suppressor protein which
is often eliminated in mesothelioma patients. The testing — called
fluorescence in situ hybridization (FISH) — makes it so doctors
can detect the deletion of p16. According to the study of FISH testing,
they found that none of the patients who had benign mesothelial tumors
tested positive for p16 deletion.
The other test reviewed used immunohistochemical testing for BAP1 loss
which is a common occurrence in patients with mesothelioma. If these tests
can prove to be valuable in diagnosing mesothelioma, it can help doctors
better treat mesothelioma patients sooner.
At Worthington & Caron, we are dedicated to helping mesothelioma patients
in any way possible. This means we are advocates for clients in litigation
and for mesothelioma research. If you have been diagnosed with mesothelioma,
we can help you find the cause and take action on your behalf.
Call us today to discuss your potential claim and learn what our firm can do to help
you. We also have an extensive network of some of the top mesothelioma
doctors in the country.